Ypsomed
Innovative, high-quality and reliable products and services which allow patients to administer their own medication in a safe and simple way.
Launch date
Employees
Market cap
€4.8b
Enterprise valuation
€5.0b (Public information from Sep 2024)
Share price
CHF427.5 YPSN.SW
Company register number CH-053.3.015.595-6
Bern Bern (HQ)
Financials
Estimates*
| CHF | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 404m | 465m | 497m | 548m | 668m | 791m | 975m |
| % growth | 2 % | 15 % | 7 % | 10 % | 22 % | 18 % | 23 % |
| EBITDA | 60.8m | 95.9m | 137m | 162m | 229m | 313m | 391m |
| % EBITDA margin | 15 % | 21 % | 28 % | 29 % | 34 % | 40 % | 40 % |
| Profit | 5.8m | 23.1m | 51.3m | 78.4m | 119m | 172m | 227m |
| % profit margin | 1 % | 5 % | 10 % | 14 % | 18 % | 22 % | 23 % |
| EV / revenue | 5.4x | 5.0x | 5.5x | 9.3x | 9.0x | 7.7x | 6.3x |
| EV / EBITDA | 36.0x | 24.1x | 20.1x | 31.6x | 26.2x | 19.5x | 15.8x |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
